IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

B. Dentz

Art Unit

: 121

Applicant

: R. A. Johnson, et al.

Serial No.

: 200,690

Filed

: 27 October 1980

For

: PGI₂ Pharmacologically Acceptable Salts

Commissioner of Patents and Trademarks

Washington, D.C. 20231

REPLY AND AMENDMENT UNDER 37 CFR 1.111 AND 1.115

Sir:

This is a response to the Examiner's first action of 18 March 1981 (Paper No. 3).

In the Claims:

Pleae cancel claim 6 and substitute therefor claim 6 (amended), attached hereto.

In the Specification:

Page 3, liñe 30, after "mixture", please insert -- of --.

Page 4, line 12, after "solution", please insert -- of --.

Page 4, line 21, after "solution", pleae insert -- of --.

REMARKS

The claims in the case are 1-5 and 6 (amended).

These claims stand rejected under 35 USC 112 in that:

- (a) the transitional phrase "consisting essentially of" allegedly renders claims 1-5 indefinite, and
- (b) the amount of the active ingredient in claim 6 and the specific intended use of the composition is not recited.

Claims 1-6 are further rejected under 35 ÚSC 103 on two grounds:

- (a) "double patenting" over the count of Interference 100,116 and
- (b) double patenting over the claims of applicants' co-pending parent application, S.N. 819,940.

Applicants respectfully request entry of the above amendments to the specification correcting an obvious and inadvertent typographical omission from the Examples. The amendments improve the readability of the Examples and introduce no new subject matter.

Applicants further respectfully request entry of amended claim 6, which likewise introduces no new subject matter, but merely limits claim 6 in the manner required by the Examiner to satisfy the require-

5/B) MAR 84-1-81